Anavex extends CEO Missling's contract through July 2025; grants 500K options tied to clinical milestones

ANAVEX LIFE SCIENCES CORP.

CEO Christopher Missling's employment agreement extended to July 5, 2025.
Base salary increased to $700,000 annually effective July 5, 2022, with target bonus of 20%.
Grant of 500,000 options vesting upon completion of three clinical trial milestones (Alzheimer’s Phase 2b/3, Parkinson’s trial initiation, Fragile X Phase 2/3 initiation).
Options exercise price equals closing price on grant date; accelerated vesting upon change in control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.